• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEEL alert in real time by email
    SC 13G/A 1 sc13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)


    Seelos Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001
    (Title of Class of Securities)
     
    81577F406
    (CUSIP Number)
     
    November 30, 2024
    (Date of Event Which Requires Filing of the Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


    ☒
    Rule 13d-1(b)

    ☐
    Rule 13d-1(c)

    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Page 1 of 5

    Cusip No. 81577F406
     
    Page 2 of 5 Pages
     
     
    1.
     
    NAME OF REPORTING PERSONS
     
    AdvisorShares Trust

     
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)  ☐    
    (b)  ☐    
     
     
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.

     SOLE VOTING POWER
     20,543
     
    6.

     SHARED VOTING POWER
     0
     
    7.

     SOLE DISPOSITIVE POWER
     20,543
     
    8.

     SHARED DISPOSITIVE POWER
     0
     
    9.

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     20,543
     
    10.

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     ☐
     
    11.

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     4.71%
     
    12.

     TYPE OF REPORTING PERSON (See Instructions)
     IV
             

    Page 2 of 5

    Cusip No. 81577F406
     
    Page 3 of 5 Pages

    Item 1(a).
    Name of Issuer:  Seelos Therapeutics, Inc.

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    300 Park Avenue
    New York, NY 10022

    Item 2(a).
    Name of Person Filing: AdvisorShares Trust

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    4800 Montgomery Lane, Suite 150
    Bethesda, Maryland 20814

    Item 2(c).
    Citizenship: Delaware

    Item 2(d).
    Title of Class of Securities: Common Stock, par value, $0.001

    Item 2(e).
    CUSIP Number: 81577F406

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    [  ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
           
     
    (b)
    [  ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
           
     
    (c)
    [  ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
           
     
    (d)
    [X]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
     
    (e)
    [ ]
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
     
    (f)
    [  ]
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
     
    (g)
    [  ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
     
    (h)
    [  ]
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    [  ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
     
    (j)
    [  ]
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
     
    (k)
    [   ]
    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
    _______________
     
    Page 3 of 5

    Cusip No. 81577F406
     
    Page 4 of 5 Pages

    Item 4.
    Ownership:

    Provide the following information regarding the aggregate number and percentage of class of securities of the issuer identified in Item 1.


    (a)
    Amount beneficially owned:  20,543


    (b)
    Percent of Class: 4.71%


    (c)
    Number of shares as to which such person has:


    (i)
    sole power to vote or to direct the vote: 20,543


    (ii)
    shared power to vote or to direct the vote: 0


    (iii)
    sole power to dispose or to direct the disposition of: 20,543


    (iv)
    shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7.
    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

    Item 8.
    Identification and Classification of Members of the Group:

    Not Applicable

    Item 9.
    Notice of Dissolution of Group:

    Not Applicable


    Page 4 of 5

    Cusip No. 81577F406
     
    Page 5 of 5 Pages

    Item 10. Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    December 4, 2024
     
    (Date)
       
     
    /s/ Stefanie Little
     
    (Signature)
       
     
    Stefanie Little – Chief Compliance Officer
     
    (Name and Title)

     

    Page 5 of 5
    Get the next $SEEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEEL

    DatePrice TargetRatingAnalyst
    9/27/2021$2.50 → $8.00Neutral → Buy
    Roth Capital
    8/10/2021$4.00 → $2.50Neutral
    Roth Capital
    7/1/2021$8.00Buy
    Guggenheim
    More analyst ratings

    $SEEL
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Seelos Therapeutics Inc.

      NT 10-Q - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)

      11/22/24 8:36:10 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seelos Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)

      11/22/24 8:35:36 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Seelos Therapeutics Inc.

      DEFA14A - SEELOS THERAPEUTICS, INC. (0001017491) (Filer)

      10/24/24 4:15:23 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Golembiewski Michael Joseph bought $100,222 worth of shares (83,000 units at $1.21), increasing direct ownership by 2,406% to 86,450 units (SEC Form 4)

      4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)

      12/1/23 4:16:44 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mehra Raj bought $99,999 worth of shares (75,757 units at $1.32), increasing direct ownership by 69% to 185,142 units (SEC Form 4)

      4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)

      12/1/23 4:16:02 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEEL
    Financials

    Live finance-specific insights

    See more
    • Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

      -A single dose of SLS-004 produced a substantial increase in recovery of tyrosine hydroxylase-positive (TH+) dopaminergic neurons that are known to degenerate in patients with Parkinson's disease -Degeneration of TH+ midbrain dopaminergic neurons in patients with Parkinson's disease is attributed to lead to the cardinal Parkinsonian symptoms of tremor, rigidity, bradykinesia and postural disturbances -Seelos management will discuss additional information about this study during the Research and Development Update Conference Call and Webcast today, December 15th at 1pm ET NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical compan

      12/15/22 8:00:00 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022

      NEW YORK, Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15th from 1pm to 3pm ET.  Registration is available at https://lifescievents.com/event/seelos-therapeutics-kol-event/, and https://seelostherapeutics.com/registration-for-12-15-rd-update-webcast/. Itinerary for the Research and Develo

      12/8/22 8:00:00 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022

      NEW YORK, Nov. 23, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET.   "As we approach, what we believe to be, a very important and catalyst heavy 2023 for Seelos, it is important that we update our investors about our progress and strategic plans," said Raj Mehra Ph.D., Chairman and CEO

      11/23/22 8:00:00 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seelos Announces Second Postponement of its Annual Meeting of Stockholders

      NEW YORK, Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024, from its originally scheduled date of Friday, September 27, 2024, has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Monday, November 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting, August 19, 2

      10/24/24 4:05:00 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

      NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that on October 14, 2024, Seelos Therapeutics, Inc. (the "Company") received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Com

      10/15/24 9:00:00 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seelos Announces Postponement of its Annual Meeting of Stockholders

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was originally scheduled to be held on September 27, 2024, has been postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024, on Friday, October 25, 2024 at 8:00 a.m., Eastern Time. The record date for the Annual Meeting August 19, 2024, is unchanged and applies to the postponed Annual Meeting.

      9/26/24 4:05:00 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

      SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

      12/4/24 1:29:12 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

      SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

      11/14/24 7:32:44 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Seelos Therapeutics Inc.

      SC 13G - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

      11/5/24 1:46:14 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Golembiewski Michael Joseph was granted 417 shares, increasing direct ownership by 0.48% to 86,869 units (SEC Form 4)

      4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)

      3/1/24 5:39:18 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mehra Raj

      4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)

      1/17/24 9:47:31 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Golembiewski Michael Joseph

      4 - SEELOS THERAPEUTICS, INC. (0001017491) (Issuer)

      1/17/24 9:47:06 PM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations

      -Richard Pascoe appointed Chairman of the Board of Directors to spearhead the ongoing business development discussions NEW YORK, April 29, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on the current discussions of potential partnerships and collaborations and announced the appointment of Richard Pascoe as Chairman of the Board of Directors of Seelos to lead the ongoing strategic process and business development discussions and negotiations. Mr. Pascoe has served as member of the Seelos board since 2019

      4/29/24 8:00:00 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors

      NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Margaret Dalesandro, Ph.D. to its Board of Directors.  Dr. Margaret Dalesandro is an accomplished biopharmaceutical executive with over 30 years of experience in drug development and commercialization. She held senior executive leadership positions at ImClone Systems, Inc. and in her role as Vice President of Project, Portfol

      9/2/21 8:00:00 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seelos Therapeutics Announces Year End 2020 Business Update

      NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year end 2020 business update. "This past year marked the most significant 12 months in Seelos Therapeutics' history despite being an otherwise challenging year due to the COVID-19 pandemic.  We completed our safety trial for the intranasal ketamine program and began opening centers for our pivotal trial for Acute Suicidal Ideation and Behavior in patients with major depressive disorder. The trehalose program's pivotal study in ALS was accepted into the

      1/6/21 8:45:00 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seelos Therapeutics upgraded by Roth Capital with a new price target

      Roth Capital upgraded Seelos Therapeutics from Neutral to Buy and set a new price target of $8.00 from $2.50 previously

      9/27/21 8:39:58 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on Seelos Therapeutics with a new price target

      Roth Capital reiterated coverage of Seelos Therapeutics with a rating of Neutral and set a new price target of $2.50 from $4.00 previously

      8/10/21 9:31:28 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Seelos Therapeutics with a new price target

      Guggenheim initiated coverage of Seelos Therapeutics with a rating of Buy and set a new price target of $8.00

      7/1/21 6:29:49 AM ET
      $SEEL
      Biotechnology: Pharmaceutical Preparations
      Health Care